

invention for use in mitigating reduction in reading speed in a subject, for example a reduction in reading speed associated with an eye disorder, such as an eye disorder disclosed herein.

5 In another aspect, the invention provides the AAV vector, cell or pharmaceutical composition of the invention for use in reducing or preventing loss of photoreceptors and/or the retinal pigment epithelium (RPE), for example a loss of photoreceptors and/or the RPE associated with an eye disorder, such as an eye disorder disclosed herein.

10 In a preferred embodiment, the AAV vector, cell or pharmaceutical composition for use according to the invention is administered intraocularly. The inventors recognise that such local administration of the therapy provides a means practically to achieve the required levels of the complement factor for treating or preventing the complement-mediated disorder of the eye, for example AMD.

15 In one embodiment, the AAV vector, cell or pharmaceutical composition of the invention is administered to the eye of a subject by subretinal, direct retinal, suprachoroidal or intravitreal injection.

In a particularly preferred embodiment, the AAV vector, cell or pharmaceutical composition of the invention is administered to the eye of a subject by subretinal injection.

20 In one embodiment, administration of the AAV vector, cell or pharmaceutical composition of the invention thereby increases the level of C3b-inactivating and iC3b-degradation activity in the subject, in particular in the eye, such as in the RPE, of the subject. In another embodiment, administration of the AAV vector, cell or pharmaceutical composition of the invention thereby increases the level of C3b-inactivating and iC3b-degradation activity in the subject, in particular in the eye, such as in the RPE, of the subject to a level that exceeds a normal level in the eye.

25 In another aspect, the invention provides a method of treating or preventing a complement-mediated disorder of the eye comprising administering the AAV vector, cell or pharmaceutical composition of the invention to a subject in need thereof.

30 In another aspect, the invention provides a use of the AAV vector, cell or pharmaceutical composition of the present invention in the manufacture of a medicament for treating or preventing a complement-mediated disorder of the eye.

In one embodiment, the disorder is associated with over-activity of the complement C3b feedback cycle and/or under-activity of the C3b breakdown cycle. In one embodiment, the

disorder is age-related macular degeneration (AMD) or diabetic retinopathy. In a preferred embodiment, the disorder is AMD, preferably dry AMD.

11. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8-10, wherein the formation of geographic atrophy is prevented or reduced, and/or the amount of geographic atrophy is reduced.
- 5 12. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8-10, wherein the progression of geographic atrophy is slowed.
13. The AAV vector, cell or pharmaceutical composition for use according to claim 12, wherein there is at least a 10% reduction in the increase in geographic atrophy area over the 12 months following administration to a treated eye of a subject, relative to an untreated eye over the same period.
- 10 14. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8-13, wherein the AAV vector, cell or pharmaceutical composition to be administered increases the level of C3b-inactivating and iC3b-degradation activity in a subject, or in an eye, such as in the retinal pigment epithelium (RPE), of a subject, optionally to a level that exceeds a normal level in a subject, or eye or RPE thereof.
- 15 15. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8-14, wherein the AAV vector, cell or pharmaceutical composition is to be administered intraocularly.
- 20 16. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8-15, wherein the AAV vector, cell or pharmaceutical composition is to be administered to the eye of a subject by subretinal, direct retinal, suprachoroidal or intravitreal injection.
17. The AAV vector, cell or pharmaceutical composition for use according to any one of claims 8-16, wherein the AAV vector, cell or pharmaceutical composition is to be administered to the eye of a subject by subretinal injection.
- 25 18. Use of the AAV vector, cell or pharmaceutical composition of any one of claims 1-7 in the manufacture of a medicament for treating or preventing a complement-mediated disorder of the eye.
19. The use of claim 18, wherein the disorder is age-related macular degeneration (AMD) or diabetic retinopathy, preferably AMD.
- 30 20. The use of claim 19, wherein the AMD is dry AMD.

21. The use of any one of claims 18-20, wherein the formation of geographic atrophy is prevented or reduced, and/or the amount of geographic atrophy is reduced.
22. The use of any one of claims 18-20, wherein the progression of geographic atrophy is slowed.
- 5 23. The use of claim 22, wherein there is at least a 10% reduction in the increase in geographic atrophy area over the 12 months following administration to a treated eye of a subject, relative to an untreated eye over the same period.
- 10 24. The use of any one of claims 18-23, wherein the AAV vector, cell or pharmaceutical composition to be administered increases the level of C3b-inactivating and iC3b-degradation activity in a subject, or in an eye, such as in the retinal pigment epithelium (RPE), of a subject, optionally to a level that exceeds a normal level in a subject, or eye or RPE thereof.
25. The use of any one of claims 18-24, wherein the AAV vector, cell or pharmaceutical composition is to be administered intraocularly.
- 15 26. The use of any one of claims 18-25, wherein the AAV vector, cell or pharmaceutical composition is to be administered to the eye of a subject by subretinal, direct retinal, suprachoroidal or intravitreal injection.
27. The use of any one of claims 18-26, wherein the AAV vector, cell or pharmaceutical composition is to be administered to the eye of a subject by subretinal injection.